Clinical research
ChemicalBook > CAS DataBase List > Senaparib

Senaparib

Clinical research
Product Name
Senaparib
CAS No.
1401682-78-7
Chemical Name
Senaparib
Synonyms
IMP4297;IMP 4297;IMP-4297;Senaparib;Senaparib (IMP-4297);Rotundine Impurity 13;Senaparib(IMP4297,JS109);5-Fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione;inhibit,poly ADP ribose polymerase,IMP 4297,Inhibitor,breast,pancreatic,IMP-4297,Senaparib,PARP,cancer,PCa;2,4(1H,3H)-Quinazolinedione, 5-fluoro-1-[[4-fluoro-3-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]phenyl]methyl]-
CBNumber
CB68080026
Molecular Formula
C24H20F2N6O3
Formula Weight
478.45
MOL File
1401682-78-7.mol
More
Less

Senaparib Property

storage temp. 
Store at -20°C
solubility 
DMSO : 83.33 mg/mL (174.17 mM; Need ultrasonic)
form 
Solid
color 
White to off-white
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

ChemScene
Product number
CS-0138656
Product name
Senaparib
Purity
99.44%
Packaging
5mg
Price
$110
Updated
2021/12/16
ChemScene
Product number
CS-0138656
Product name
Senaparib
Purity
99.44%
Packaging
10mg
Price
$190
Updated
2021/12/16
ChemScene
Product number
CS-0138656
Product name
Senaparib
Purity
99.44%
Packaging
25mg
Price
$350
Updated
2021/12/16
ChemScene
Product number
CS-0138656
Product name
Senaparib
Purity
99.44%
Packaging
50mg
Price
$550
Updated
2021/12/16
ChemScene
Product number
CS-0138656
Product name
Senaparib
Purity
99.44%
Packaging
100mg
Price
$950
Updated
2021/12/16
More
Less

Senaparib Chemical Properties,Usage,Production

Clinical research

Senaparib is a PARP inhibitor that demonstrated antitumor activity in patients with solid tumours, including ovarian cancer, in phase 1 studies. The multicenter, double-blind, phase 3 trial FLAMES randomized (2:1) 404 females with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III–IV) and response to first-line platinum-based chemotherapy to senaparib 100 mg (n = 271) or placebo (n = 133) orally once daily for up to 2 years. The primary endpoint was progression-free survival assessed by a blinded independent central review. At the prespecified interim analysis, the median progression-free survival was not reached with senaparib and was 13.6 months with placebo (hazard ratio 0.43, 95% confidence interval 0.32–0.58; P < 0.0001). The benefit of senaparib over placebo was consistent in the subgroups defined by BRCA1 and BRCA2 mutation or homologous recombination status. Grade ≥3 treatment-emergent adverse events occurred in 179 (66%) and 27 (20%) patients, respectively.

Description

Senaparib is a novel and potent PARP1 inhibitor with a unique chemical structure and high inhibitory activity. Research has found that Senaparib not only effectively inhibits the enzymatic activity of PARP1 and PARP2 but also induces the "trapping" of PARP1 on DNA, leading to the stalling of DNA replication forks and double-strand DNA breaks, ultimately causing cell death. This "trapping" effect is considered a key factor in the therapeutic efficacy of PARP1 inhibitors.

Senaparib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Senaparib Suppliers

TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32161
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38631
Advantage
58

1401682-78-7, SenaparibRelated Search:


  • Senaparib
  • 2,4(1H,3H)-Quinazolinedione, 5-fluoro-1-[[4-fluoro-3-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]phenyl]methyl]-
  • IMP 4297
  • IMP4297
  • IMP-4297
  • inhibit,poly ADP ribose polymerase,IMP 4297,Inhibitor,breast,pancreatic,IMP-4297,Senaparib,PARP,cancer,PCa
  • Senaparib (IMP-4297)
  • 5-Fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione
  • Senaparib(IMP4297,JS109)
  • Rotundine Impurity 13
  • 1401682-78-7
  • C24H20F2N6O3